Format

Send to

Choose Destination
Expert Rev Neurother. 2009 Feb;9(2):197-210. doi: 10.1586/14737175.9.2.197.

CADASIL management or what to do when there is little one can do.

Author information

1
Neurovascular Research Laboratory and Neurovascular Unit, Vall d'Hebrón Hospital, Neurology Department-Universitat Autònoma de Barcelona, Spain.

Abstract

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a rare disease that leads to migraine, mood disorders, recurrent lacunar strokes and early vascular dementia. This autosomal-dominant condition is caused by mutations in the NOTCH3 gene and is characterized by degeneration of vascular smooth muscle cells. At present, no evidence-based treatment for CADASIL is available and only relief of symptoms can be offered to patients. This review focuses on an update of CADASIL management, based on the recent clinical and basic evidence, and discusses possible new treatment targets for CADASIL.

PMID:
19210195
DOI:
10.1586/14737175.9.2.197
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center